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Introduction: Although stem cell therapy is a promising treatment for myocardial infarction, the minimal functional
improvements observed clinically limit its widespread application. A need exists to maximize the therapeutic
potential of these stem cells by first understanding what factors within the infarct microenvironment affect their
ability to regenerate the necrotic tissue. In this study, we assessed both differentiation capacity and paracrine
signaling as a function of extracellular matrix remodeling after myocardial infarction.
Methods: Mechanical and compositional changes to the decellularized infarcted myocardium were characterized
to understand how the extracellular environment, specifically, was altered as a function of time after coronary artery
ligation in Sprague–Dawley rats. These alterations were first modeled in a polyacrylamide gel system to understand
how the variables of composition and stiffness drive mesenchymal stem cell differentiation towards a cardiac
lineage. Finally, the paracrine secretome was characterized as a function of matrix remodeling through gene and
protein expression and conditioned media studies.
Results: The decellularized infarct tissue revealed significant alterations in both the mechanical and compositional
properties of the ECM with remodeling following infarction. This altered microenvironment dynamically regulates
the potential for early cardiac differentiation. Whereas Nkx2.5 expression is limited in the presence of chronic
remodeled matrix of increased stiffness, GATA4 expression is enhanced. In addition, the remodeled matrix promotes
the expression of several proangiogenic, prosurvival, antifibrotic, and immunomodulatory growth factors. In
particular, an increase in HGF and SDF1 expression and secretion by mesenchymal stem cells can rescue oxidatively
stressed cardiomyocytes in vitro.
Conclusions: This study demonstrated that decellularization of diseased tissue allows for the exclusive analysis of
the remodeled matrix and its ability to influence significantly the cellular phenotype. Characterization of cell fate as
a function of myocardial remodeling following infarction is critical in developing the ideal strategy for cell
implantation to maximize tissue regeneration and to ultimately reduce the prevalence and severity of heart failure.Introduction
The prevalence and severity of heart failure following
myocardial infarction (MI) warrants the investigation
into new and innovative treatment options [1]. The
most commonly studied approach is stem cell therapy,
which strives to regenerate the necrotic myocardium with* Correspondence: lauren.black@tufts.edu
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reproduction in any medium, provided the ormulti- or pluripotent stem cells capable of rescuing the
organ through their differentiation toward contractile car-
diomyocytes or proangiogenic and prosurvival paracrine
signaling to native cells of the injured heart [2-6]. How-
ever, clinical trials with unfractionated mononuclear bone
marrow cells have only demonstrated the ability to pro-
mote a slight increase in contractility in those patients
with a severe MI [7,8]. Identifying which variables within
the infarct environment regulate their regenerative poten-
tial in vivo is critical in developing the ideal implantation
strategy to maximize the functional benefits achieved after
injection [6,9].l Ltd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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evidence about the cardiac differentiation potential of
MSCs within the necrotic scar and whether those
cells that do integrate and express markers of a myo-
genic lineage contribute to functional repair [10]. Many
researchers have argued that their ability to decrease in-
farct volume and promote contractility is most com-
monly through their release of soluble factors, which
have demonstrated the ability to (a) promote survival of
stressed and necrotic cardiomyocytes [11,12], (b) initiate
angiogenesis to restore oxygen and nutrient delivery
[13], (c) alter the inflammatory cascade [14], (d) assist in
stem cell homing [15], and (e) limit excessive remodeling
with antifibrotic factors [16]. However, the MSC secre-
tome after implantation is poorly understood, and to
harness its full potential, we must characterize what
factors within the infarct microenvironment drive its
expression profile [17].
The significance of the extracellular matrix (ECM) in
the development and function of tissues and organ sys-
tems has been reevaluated and is now identified as a
collection of signaling moieties that take part in the bi-
directional exchange between the intracellular and
extracellular environments [18]. Therefore, recent stud-
ies have reconsidered the role of cellular and ECM
interactions and the critical functions that these inter-
actions have throughout development, native tissue
function, and disease progression [19-21].
Research has demonstrated that the differentiation
potential of MSCs is regulated by both substrate com-
position [22] and stiffness [23]. However, these studies
have identified only the independent effects of these
two variables, but given the crosstalk between compos-
ition and stiffness [24-26], it is important to consider
how they influence cells both synergistically and antag-
onistically. In addition, although studies have shown
that both differentiation and growth-factor stimulation
in the heart is integrin mediated [27], in vitro studies
have focused on the effects of singular ECM proteins,
whereas the native matrix is a complex milieu of pro-
teins, glycoproteins, and polysaccharides [28]. With the
development of decellularization techniques [29], re-
searchers have been able to explore and predict how
this dynamic network regulates cell fate in vivo
through in vitro studies. For example, recent studies
have demonstrated that complex cardiac ECM pro-
motes cardiomyocyte proliferation [30], progenitor cell
differentiation toward a cardiac lineage [31], and con-
tractility of the left ventricle when injected after MI
[32]. Given that the extracellular environment is sig-
nificantly remodeled as a function of time after infarc-
tion, with dramatic alterations in both stiffness and
composition [33], it is critical to understand how these
changes affect the therapeutic potential of MSCs.In this study, we investigated how the altered biophys-
ical properties of the myocardium after MI affect the re-
generative potential of MSCs in vitro. The mechanical
and compositional changes to the extracellular environ-
ment were first characterized as a function of time after
MI, and early and late infarct environments were reca-
pitulated in a polyacrylamide gel system. Although the
potential of MSCs for functional cardiac differentiation
is questionable [34-37], our work demonstrated that
both the increased stiffness and altered matrix compos-
ition of the late infarct environment severely abrogated
the expression of the early cardiac transcription factor
Nkx2.5. In contrast, the remodeled matrix (both com-
position and stiffness) enhanced the expression of an-
other cardiac transcription factor, GATA4.
We also investigated alterations in paracrine signaling
in response to infarct matrix and determined that the
late, remodeled matrix significantly enhances the expres-
sion of several growth factors, including HGF (an antifi-
brotic and angiogenic growth factor) and SDF1 (a stem
cell homing and prosurvival factor). Conditioned media
from cells cultured in the presence of the remodeled
matrix had the greatest potential to rescue cardiomyo-
cytes after oxidative stress in vitro. We hypothesize that
the enhancement of GATA4 expression observed within
the late infarct environment promotes the release of
beneficial soluble factors by MSCs. The goal of this
study was to identify how the remodeled ECM environ-
ment after infarction affects the early cardiac differenti-
ation potential and paracrine signaling of MSCs.
Methods
Characterization of extracellular environment after MI
Decellularization of infarcted myocardium
All animal experiments were performed in accordance
with the US Animal Welfare Act and institutional guide-
lines and were approved by the Institutional Animal
Care and Use Committee at Tufts University. MI was
induced in male Sprague–Dawley rats (250 to 275 g) by
permanently ligating the left coronary artery with a 6–0
Prolene suture. Generation of a significant infarct was
verified if 40% or more of the left ventricle was blanched
after artery ligation. Animals with a significant infarct
were allowed to recover for 1, 2, or 4 weeks. Hearts were
isolated at the respective time points and underwent
retrograde perfusion decellularization with 1% sodium
dodecylsulfate (SDS) by ligating the three major branches
of the transverse aortic arch and advancing an 18-G can-
nula through the descending aorta. Decellularization was
confirmed when the tissue became translucently clear,
usually after 48 to 72 hours of perfusion with 3 to 6 L of
1% SDS (Figure 1A). Previous work verified that decellu-
larization with this method is successful by the absence of
cellular DNA [29].
Figure 1 Characterization of decellularized myocardial infarcts as a function of remodeling time. (A) The decellularized scar appears
physically distinct from the noninfarcted region of the myocardium. (B) Representative confocal images acquired 25 μm from tissue surface.
Composite images demonstrate an increase in collagen deposition after infarct (Forward SHG in red, backward SHG in green, two-photon excited
fluorescence (TPEF) emission between 500 and 550 nm in blue). (C) Representative stress–strain curves derived from mechanically testing
decellularized myocardial strips derived from both healthy left ventricular tissue and 4-week scar tissue. (D) The tangent modulus of the left
ventricle increases with remodeling time after myocardial infarction (n = 4 to 6 for each condition).
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generation imaging
Regions of the decellularized scar were sectioned into
strips and imaged via nonlinear optical microscopy. Im-
ages were acquired on a Leica TCS SP2 confocal micro-
scope equipped with a Ti:sapphire laser (Spectra Physics,
Mountain View, CA, USA) tuned to 800 nm. By using a
63× objective (1.2 NA), image stacks (512 × 512 pixel,
238 × 238 μm2 field of view) were acquired at 5-μm in-
crements from the surface of the tissue by using a set of
non-descanned PMTs. Second harmonic generation (SHG)
images were collected in the backward and forward direc-
tion by using 400 (±10)-nm bandpass filters. To measure
collagen cross-link fluorescence, TPEF was simultaneously
measured by using a 525 (±25)-nm filter. Image intensities
were normalized for PMT gain and laser power, as previ-
ously described [38]. The average backward SHG, forward
SHG, and TPEF intensities within the first 100 μm from
the tissue surface were computed from each acquired
image volume.
Mechanical characterization of decellularized infarcted
myocardium
Because of the nondestructive nature of the optical-
imaging protocol, the mechanical properties of the im-
aged samples were also analyzed by using a previously
described setup [39]. A custom-built imaging-based de-
vice was used to measure the thickness of the tissuesamples, whereas Vernier calipers measured both the
width and length of the tissue. These measurements
were used to calculate the initial cross-sectional area of
the sample to convert force values to stress measure-
ments. Excess moisture was removed from the samples
before they were mounted on two footplates with cyano-
acrylate. The sample was submerged in a bath of 1× PBS,
and the plates were carefully aligned onto a custom-built
uniaxial mechanical stretcher. One foot was held in a fixed
position, whereas the other was connected to a lever arm
with the capacity to measure and control both displace-
ment and force (model 400B; Aurora, Ontario, Canada).
All measurements were made in the circumferential direc-
tion of the heart, as this is the overall average alignment of
the ECM in the ventricular wall [40]. Samples were pre-
conditioned with 10 cycles of quasi-static (45 mm/min)
displacement to 60% strain. Samples were allowed 2 mi-
nutes of viscoelastic recovery in an unloaded configur-
ation and then exposed to 100% strain for six cycles. The
sixth cycle was analyzed, and the tangential modulus
was calculated in the linear region of the stress–strain
curve, which was typically between 70% and 80% strain.
(See Figure 1C for sample stress–strain curves (n = 4 to
6 for each condition)).
Compositional analysis of infarcted myocardium
Compositional changes to the decellularized infarcted
myocardium were assessed with a variety of methods.
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Total Collagen Assay (QuickZyme Biosciences, Voorhout,
The Netherlands). In brief, the infarcted region of the
decellularized ECM was frozen overnight at −20°C and
then lyophilized for 24 hours. Dry tissue was weighed and
hydrolyzed in 12M HCl for 20 hours at 95°C. Dilutions of
hydrolyzed samples were prepared to obtain absorbance
measurements within the range of the standard curve,
according to the instructions on the kit (n = 3 for each
condition). Samples were also prepared for liquid chroma-
tography–tandem mass spectroscopy (LC-MS/MS) through
a urea digestion at 4°C with constant agitation via a stir bar
after lyophilization for 48 hours. Protein was collected
through an acetone precipitation and frozen until samples
were sent to the Beth Israel Deaconess Medical Center
Mass Spectroscopy Core Facility for further analysis.




ECM was isolated from decellularized, healthy, and
infarcted hearts at 1 and 4-week time points, as de-
scribed previously. ECM was perfused with 50 ml
diH20 after decellularization with 1% SDS. Whole
decellularized hearts were then washed with 50 ml of
0.5% triton X and rinsed again with diH20. Hearts were
then washed with 1× PBS through perfusion with a
peristaltic pump for 72 hours. PBS was changed every
12 hours. The scar region of the decellularized myocar-
dium was minced and frozen at −20°C overnight. Sam-
ples were lyophilized, and dry weight measured. Tissue
was solubilized as described previously [41,42]. In brief,
matrix was solubilized in a 1 mg/ml solution of pepsin
in 0.1M HCl to reach a final solubilized ECM concen-
tration of 10 mg/ml.
Glass-slide activation and polyacrylamide (PA) gel
formation
To create binding sites for the PA gels, 22 mm × 22 mm
glass cover slips were activated by following previously
described protocols [43]. Slides were passed over an
open flame and smeared with 0.1M NaOH, followed by
3-aminopropyltrimethoxysilane. Slides were then trans-
ferred to six-well plates and washed with diH20 on an
orbital shaker. Water was aspirated, and glass cover slips
were incubated in 0.5% glutaraldehyde for 30 minutes.
Glutaraldehyde was removed, and slips were washed in
diH2O for three 5-minute washes. Activated glass cover
slips were stored in diH2O at 4°C for up to 4 weeks or
until use.
PA gels were created at two different stiffnesses (25
and 40 kPa), consistent with previously collected mech-
anical data; corresponding to healthy myocardium andinfarct myocardium after CF remodeling by changing
the amount of cross-linking between acrylamide and bis-
acrylamide. Gels of 25 kPa stiffness were generated with
10% acrylamide and 0.1% bis-acrylamide, whereas 40 kPa
gels were created with 10% acrylamide and 0.2% bis-
acrylamide. Gel stiffness was confirmed through mech-
anical testing with the custom-built uniaxial mechanical
stretcher described previously. 400 μg of ECM from
each time point was cross linked into 500 μL of PA gel
solution of both stiffnesses (25 or 40 kPa) by using N-
hydroxysuccinimide (NHS) ester to create covalent link-
ages between amine groups. Rat-tail collagen I (BD Bio-
sciences, San Jose, CA, USA) was incorporated into gels
to function as a control protein. HCl was added to the
gel to lower the pH to 6.6 to prevent the hydrolysis of
NHS. Cross-linking of the acrylamide to bis-acrylamide
was achieved with the final incorporation of TEMED
and 10% ammonium persulfate (APS).
Activated coverslips were dried in a sterile cell-culture
hood, and 30 μl of each gel solution was cast onto a
glass coverslip. A nonactivated coverslip was then placed
on top of the gel solution to promote polymerization
and create an even gel surface. Gels were allowed to
polymerize for 30 minutes, and then the nonactivated
glass coverslip was removed with a razor blade. Gels
were transferred to sterile six-well plates and washed
with sterile 1× PBS 3 times for 5 minutes.
Cell culture
Primary isolated rat mesenchymal stem cells (rMSCs)
were purchased from Cell Applications (San Diego, CA,
USA) and cultured in maintenance medium containing
15% FBS in αMEM with 1% Pen-Strep and 2% L-glutam-
ine. Cells were passaged at 80% confluence, and only
cells between passages 3 and 6 were included in this
study. 30,000 cells were seeded onto each gel and cul-
tured in 20% oxygen in maintenance medium. Cells were
also cultured on TCP as a negative control. 24 hours
after seeding, gels were transferred to new sterile six-
well plates to minimize paracrine signaling between cells
seeded on the TCP and cells on gels. Cells were fed
every other day and analyzed after 1 week in culture
through histology and Western blotting.
Histology
Cells cultured on polyacrylamide gels were fixed on day
7 in methanol for 10 minutes at 4°C on an orbital
shaker. Cell membranes were permeated through a treat-
ment with 0.05% triton-X for 5 minutes and then rinsed
3 times for 5 minutes in 1× PBS. Samples were blocked
in a 5% donkey serum and 0.1% BSA solution in 1× PBS
for 1 hour at RT. Primary antibodies for Nkx2.5 and
GATA4 (sc-14033 and sc-25310, respectively; Santa-
Cruz) were diluted 1:200 in a 0.1% BSA solution. Cells
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and then rinsed 3 times for 5 minutes. Secondary anti-
bodies (Alexa Fluor 488-conjucated donkey anti-rabbit
715-545-152, Cy3-conjugated donkey anti-mouse 715-
165-150; Jackson ImmunoResearch, West Grove, PA,
USA) were diluted at 1:400 in 0.1% BSA solution in PBS.
Cells were incubated in the secondary solution for 1 hour
at RT. After three 5-minute rinses in PBS, cells’ nuclei
were stained with a 1:10,000 dilution of Hoescht fluores-
cent dye for 5 minutes (Hoescht 33258; Invitrogen).
Samples were washed in PBS (3 × 5 min) and then im-
aged with an Olympus IX 81 fluorescent microscope. In
brief, gels were inverted on a glass slide, and two repre-
sentative images were acquired per condition.
Protein isolation and quantification
To quantify the differentiation capacity of the cells
within the infarct environments, cells were treated with
0.05% trypsin for 5 minutes and then quenched with
fetal bovine serum. Samples were collected via centrifu-
gation at 500 rpm. Supernatant was removed, and pellets
were washed with 1× PBS. Samples were collected
after a second 500 rpm centrifugation, and pellets were
resuspended in ice cold cell lysis buffer consisting of
NP40, 40× sodium deoxycholate, sodium orthovanadate,
aprotinin, pepstatin, leupeptin, and diH2O, as previously
described [44]. Samples were sonicated on ice for 20 sec-
onds at 30% amplitude, rotated end over end on a rotis-
serie for 15 minutes at 4°C and then centrifuged at
13,000 rpm for 15 minutes at 4°C. Total protein was
quantified with a Pierce BCA assay.
Western blotting
Based on the BCA protein assay, the lanes of 4% to 15%
gradient gels (456–1083; Biorad, Hercules, CA, USA)
were loaded equally with protein from each condition
(typically ranging between 5 and 15 μg). Protein samples
were mixed with sample buffer and dithiothreitol and
placed on a heat block at 95°C for 5 minutes. Samples
were vortexed and briefly centrifuged before loading.
Gels were run at 100 V/gel for approximately 35 minutes
until the dye front reached the edge of the gel. Protein
was transferred onto a nitrocellulose membrane at max-
imum current (400 mA) for 2 hours. Blots were blocked
in 5% milk in TBST (Tris-buffered saline and 10%
Tween 20) and probed for Nkx2.5 (SAB2101601; Sigma-
Aldrich) and GATA4 (sc-25310; Santa Cruz). Samples
were incubated in a 1:400 primary antibody dilution for
at least 1 hour at room temperature. Blots were rinsed 3
times for 5 minutes in TBST before incubation in a
1:1,000 dilution of secondary HRP-conjugated antibody
(715-035-150 and 711-035-152; Jackson ImmunoRe-
search, West Grove, PA, USA). After three 5 minute
rinses in TBST, blots were developed with enhancedchemiluminescence (ECL) reagents on G: Box Chemi
XR5 (Syngene, Cambridge, UK). Expression of the
cardiac transcription factors was normalized to cellular
β-actin expression (primary 1:1,000 (A5316; Sigma-
Aldrich) and secondary 1:5,000 (715-035-150, Jackson
ImmunoResearch)). Band intensities were quantified
with ImageJ software (NIH, Bethesda, MD, USA) (n = 5
for each condition).
Paracrine secretome studies
Healthy and infarcted matrix of respective time points
were solubilized and adsorbed onto 24-well TCP plates
at a density of 50 μg/cm2. Rat tail collagen I and human
plasma fibronectin (Millipore, Billerica, MA, USA) were
used as control matrix proteins and adsorbed
at the same density. Matrix was diluted in DMEM,
applied to wells, and allowed to dry overnight in a
sterile biological hood. After three 5 minute rinses with
1× PBS, 500,000 MSCs were seeded per well in 10%
fetal bovine serum and 1% Pen-Strep in IMDM. Then
24 hours after seeding, media was changed to a serum
and antibiotic-free condition consisting of only IMDM.
After 24 hours, cells were isolated for quantitative PCR,
and media was collected, centrifuged at 1,000 rpm for
5 minutes, and stored at −80°C for ELISAs and condi-
tioned media studies.
Quantitative PCR
Cells were isolated with 0.05% trypsin for 5 minutes and
then quenched with fetal bovine serum. Samples were
collected via centrifugation at 500 rpm. Supernatant was
removed, and pellets were washed with 1× PBS. Samples
were collected after a second 500 rpm centrifugation,
and RNA was isolated with the RNAeasy kit (74104,
Qiagen). Extracted RNA was quantified, and 500 ng was
treated with Genomic DNA Elimination mix (Qiagen)
and reverse transcribed into cDNA with the Qiagen RT2
First Strand Kit in a thermocycler. The two-step reaction
consisted of 15 minutes at 42°C followed by 5 minutes
at 95°C. The 20 μl reverse-transcription reaction was
diluted in 91 μl of nucleotide-free water. Then 17 μl of
the diluted reaction was combined with 225 μl of RT2
SYBR Green ROX qPCR Mastermix from Qiagen and
diluted with nuclease-free water to reach a final volume
of 450 μl. 25 μl of each reaction was applied to
the designated wells of a Custom PCR array ordered
through SABiosciences, a Qiagen Company. The array
was designed to interrogate the expression of 11 genes
implicated for their ability to restore function to the in-
farct through paracrine signaling when expressed by
MSCs and included vegfa, fgf2, pgf, pdgfb, hgf, igf1, tnf,
il10, tgfbr2, cxcl12 and akt1.
In addition, the array plate contained two housekeep-
ing genes, β-actin and β2-microglobulin, as well as three
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ation, PCR, and reverse transcription efficiency. The
array plates are designed to assay six biologic samples
for all 16 markers simultaneously. Real-time PCR reac-
tions were carried out on a Stratagene Mx3000P ther-
mocycler in three segments. The first segment consisted
of a single cycle performed at 95°C for 10 minutes. Seg-
ment 2 consisted of 40 subsequent cycles beginning with
15 seconds at 95°C, followed by 1 minute at 60°C, and
ending with fluorescence data collection. Last, segment
3 was carried out for melting curve analysis and con-
sisted of a single cycle at 95°C for 1 minute, followed by
55°C for 30 seconds, fluorescence data collection, and
ending with 30 seconds at 95°C.
Primer specificity was verified by a single dissociation
curve achieved for each gene of interest. Ct values were
calculated at a threshold fluorescence of 0.075 for all
plates. Fold change expression was calculated by using
the ΔΔCt method [39] (n = 6 for each condition).
Enzyme-linked immunosorbent assays
Conditioned media was thawed on ice, and 50 μl of each
sample was analyzed with an HGF ELISA kit (R&D Sys-
tems), whereas 100 μl was analyzed with an SDF1 SDF1
ELISA kit (USCN Life Science). Assays were performed
according to the manufacturer’s instructions (n = 6 for
each condition).
Conditioned media studies
Neonatal rat cardiomyocytes were isolated through a
collagenase digestion of the entire heart followed by pre-
plating for 1 hour to achieve a cardiomyocyte-rich popu-
lation, as described previously. Cells were seeded on
48-well plates at a density of 50,000 cells/cm2 in serum
containing media (10% horse serum, 2% fetal bovine
serum, 1% pen-step in DMEM) and fed every other day.
Then 5 days after seeding, media was changed to a
serum-free media (50:50 mixture of DMEM and Ham’s
F12 Nutrient Mix, 0.2% BSA (wt/vol) (Sigma), 0.5% insu-
lin–transferrin–selenium-X (Invitrogen), and 1% pen-
strep, with 0.1 mM ascorbic acid (Sigma)). 24 hours
later, media was replaced with a 50:50 mixture of condi-
tioned media and IMDM [45]. Complete IMDM was
given as a negative control. 1 hour later, media was
spiked with 300 μM H2O2 for 4 hours [46], and cell
death was assessed through a Live/Dead cell viability
assay (Invitrogen) (n = 6 for each condition).
Statistics
All results were analyzed with appropriate-sized multiple
univariate analysis of variance with Student t test post
hoc t testing, and P values less than 0.05 were consid-
ered statistically significant. Trends with a P value less
than 0.1 are also identified.Results
Infarct characterization
MI was successfully induced in male Sprague–Dawley
rats, as demonstrated by ventricular free wall thinning in
the scar region of the infarcted heart after decellulariza-
tion (data not shown). The infarcted myocardium ap-
pears physically distinct from the noninfarcted region,
because the increased density of the ECM makes it ap-
pear more opaque (Figure 1A, right), allowing for exclu-
sive analysis of the more significantly remodeled tissue.
At 1 week post-MI, the scar matrix increases signifi-
cantly (P < 0.05). 2 and 4 weeks post-MI, the tissue is
significantly stiffer than both the healthy and 1 week
infarct matrix (P < 0.05) (Figure 1C). This increase in
stiffness may be related to a significant increase in the
number of small diameter fibers deposited throughout
the tissue after MI, as revealed by SHG imaging
(Figure 1B). The average image volume backward SHG
intensity decreased 25% from 99.9 to 74.6 a.u. between
healthy tissue and 1 week after MI, with intensities in-
creasing over the following weeks to an average value of
118.9 at week 4 (19% increase relative to healthy tissue).
A much weaker SHG intensity was collected in the for-
ward direction (Figure 1B), which may be affected by
light scattering through these thick tissue samples. Inter-
estingly, the average TPEF image intensity was 59% to
67% lower at all postinfarct time points relative to
healthy tissue, suggesting fewer elastin or collagen cross-
links present in each average volume.
Compositional analysis confirmed that the most sig-
nificant changes to the ECM composition occur after CF
activation (usually thought to occur around 2 weeks
after MI). At 1 week after MI, a slight, although not sig-
nificant increase in total collagen is measured by a total
collagen assay. At 4 weeks after MI, the increase in col-
lagen is significant (P < 0.05) (Figure 2A). Spectrum-
count analysis of LC-MS/MS data revealed dramatic
alterations in protein composition after MI (Figure 2B).
In the healthy heart, laminin, fibronectin, and collagen I
comprise nearly 70% of the total protein within the
heart. However, the complexity of the composition is
highlighted by the presence of periostin, elastin, collagen
III, collagen V, and other collagen isoforms. At 1 week
after MI, there are noticeable alterations in the compos-
ition of the scar. In particular, periostin expression in-
creases nearly fivefold, as well as slight increases in
fibronectin and collagen VI. While total elastin content
remains the same, there is a decrease in laminin and col-
lagen I expression. In general, the matrix is composed of
relatively similar proportions of total collagen (43% col-
lagen in healthy heart versus 38% at 1 week after MI).
The most significant alterations in composition are ob-
served at the 4 week time point. Collagen I comprises
57% of all matrix proteins, and 85% of the composition
Figure 2 Characterization of the infarct matrix composition after myocardial infarction. (A) Total collagen content within the 4-week
infarct is significantly greater than both the healthy and 1-week conditions (n = 3 for each condition and P < 0.05). (B) LC-MS/MS spectrum count
analysis describes the relative percentages of each matrix protein identified within the decellularized healthy left ventricle or scar. Note that Pstn
is periostin, Ln is laminin, Eln is elastin, Fn is fibronectin, and Col is collagen. (n = 2 for each condition).
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represent the other 15% of the composition. These re-
sults demonstrate the dynamic remodeling process that
occurs after MI.
Generation of in vitro cell-culture platform
Polyacrylamide gels were mechanically tested to confirm
the stiffness corresponded to both healthy and diseased
myocardium (Figure 3). The incorporation of solubilized
ECM of both healthy and infarcted hearts into the gels
provided binding sites for MSCs. Histologic analysis
confirmed the ability of cells to adhere to and survive on
the gels for more than 1 week (Figure 3).
Assessment of MSC differentiation
Histologic analysis reveals that MSCs cultured in the gel
containing healthy, decellularized cardiac ECM at a
physiologically relevant stiffness (25 kPa) express the
early cardiac transcription factors, Nkx2.5 and GATA4
(Figure 4). However, a significant decrease in the expres-
sion of these markers was observed on gels of higher
stiffness (40 kPa). Note that Nkx2.5 expression is pri-
marily in the nucleus, with diffuse staining in the cyto-
plasm. Similarly, cells cultured on gels of decellularized
infarct ECM isolated 1 week after induction of an infarct
expressed only Nkx2.5 and GATA4 robustly on gels of
a 25 kPa stiffness, whereas expression was minimal ongels of 40 kPa stiffness. Limited Nkx2.5 expression was
observed when cells were cultured on gels with 4 week
matrix of either stiffness. In contrast, GATA4 expression
appeared robust on gels of increased stiffness containing
4 week infarct matrix. Minimal expression of either
marker was observed on MSCs cultured on tissue
culture plastic.
Western blot analysis of total cell lysate revealed simi-
lar trends regarding the influence of biophysical cues
of the infarct on the expression of cardiac markers
(Figure 5). The most robust expression of Nkx2.5 was
observed by cells cultured on gels of 25 kPa stiffness
with healthy and 1 week infarct ECM, as compared with
all other conditions (P < 0.05) (Figure 5). Cells cultured
on 4 week matrix on gels of either stiffness did not ex-
press significantly more Nkx2.5 than cells cultured on
TCP. Conversely, the 4 week infarct ECM significantly
promoted the expression of GATA4 on gels of 40 kPa
stiffness, as compared with both healthy and the control,
TCP (P < 0.05) (Figure 5). However, no significant differ-
ence in GATA4 expression was seen when gels were cul-
tured on 4 week matrix of a lower, 25 kPa stiffness. We
performed a preliminary study with gels incorporated
with Collagen I and did not see significant expression of
Nkx2.5 or GATA4 through immunohistochemistry. This
was further confirmed through Western blotting (see
Additional file 1: Figure S1).
Figure 3 Schematic of the development of an in vitro cell-culture platform to characterize MSC fate within infarct microenvironment.
Whole hearts isolated from both healthy and infarcted (1- and 4-week time points) animals are decellularized, solubilized, and incorporated into
polyacrylamide gels of stiffnesses corresponding to both healthy and infarcted myocardium. Histologic analysis reveals that cells attach and
spread along the gels (scale bar is 100 μm).
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remodeling after I
Of the soluble factors assayed, hgf and cxcl12 expression
were both significantly altered as a function of matrix
composition (Figure 6). The expression of both pro-
survival growth factors was greatest in the presence
of the chronic infarct matrix. Although the expres-
sion of proangiogenic (pdgfb, vegfa, fgf2, and pgf ) andFigure 4 Early cardiac differentiation is abrogated by the infarct micr
polyacrylamide gels modeling the various infarct environments of our cell-
blue. Scale bar is 100 μm.immunomodulatory (tgfbr2 and il10) factors were also
elevated in the presence of the 4 week matrix, as com-
pared with both the healthy and 1 week matrices, these
trends did not maintain significance across multiple
matrix isolations because of the inherent variability asso-
ciated with matrix remodeling (Figure 6). However, the
enhanced expression levels of cxcl12 and hgf were up-
held across both single and multiple matrix isolationsoenvironment. Representative histologic images of MSCs cultured on
culture system. Nkx2.5 is red, GATA4 is green, and Dapi nuclear stain is
Figure 5 Protein expression of early cardiac transcription factors is influenced by infarct microenvironment. Representative Western
blot images for both cardiac transcription factors (Nkx2.5 and Gata4) as well as a housekeeping gene (β-actin) are presented. Relative expression
levels for each cardiac marker are normalized to β-actin and presented for each condition. For the Nkx2.5 plot, the healthy, 25-kPa condition is
significantly higher than all other conditions. For GATA4, the 4 week, 40 kPa condition is significantly greater than the TCP condition and the
healthy, 40 kPa gel condition (*P < 0.05 and n = 5 for each condition).
Figure 6 Evaluation of MSC secretome as a function of matrix composition through mRNA expression. The average fold change in mRNA
expression ± the standard deviation for proangiogenic, prosurvival, and immunomodulatory factors is calculated relative to cells cultured on TCP.
The data are averaged over multiple matrix isolations (n = 6). The color scaling of each cell denotes the degree to which the expression is
upregulated (red intensity), downregulated (blue intensity), or maintained constant (white). The conditions in which the growth factor expression
is significantly upregulated are denoted by an asterisk.
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affected functional outcomes, we looked at the release
of HGF and SDF1 by MSCs in the presence of healthy,
1 week, and 4 week ECM, each derived from a single
isolation. ELISAs demonstrated that both growth factors
were present in the conditioned media at the greatest con-
centration when cells were cultured on 4 week matrix
(P < 0.05). However, it appears that the healthy matrix in-
hibits the production and release of SDF1, as compared
with the 1-week matrix or TCP (P < 0.05) (Figure 8). Alter-
natively, HGF is down-regulated on the 1 week matrix as
compared to the healthy. However, all of the three matri-
ces promote HGF secretion compared with TCP (P < 0.05)
(Figure 8). This increase in prosurvival growth factors in
the media of cells cultured on healthy, short term, and
long term infarcted matrix was able to rescue oxidatively
stressed cardiomyocytes in vitro as compared with those
cells cultured on TCP (Figure 9).
Discussion
Extensive research has demonstrated how the extracellular
environment plays a critical role in regulating cellular,Figure 7 The mRNA expression of prosurvival growth factors is
modulated by matrix composition. The fold change in mRNA
expression for cxcl12 and HGF is calculated relative to cells cultured
on TCP. The data are presented for both a single ECM isolation
(n = 3) and data averaged over multiple matrix isolations (n = 6).
For both genes, the 4 week time point has significantly higher
expression than either the healthy or 1 week condition. A single
* represents P < 0.1, and ** represents P < 0.05.
Figure 8 SDF1 and HGF concentrations in conditioned media
samples are modulated as a function of substrate composition.
SDF1 is present at the highest concentration in conditioned media
derived from MSCs cultured on healthy and 4 week matrix (P < 0.05).
However, cells cultured on 1 week matrix secrete more SDF1 into
the media than do those cultured on TCP (n = 3). The concentration
of HGF in conditioned media samples derived from cells cultured
on 4-week matrix is significantly higher than healthy matrix or TCP
(P < 0.05). Cells cultured on healthy matrix secrete significantly less
HGF than those under all other conditions (P < 0.05) (n = 3).tissue, and whole-organ physiology [19-21]. Therefore, it
is necessary to understand how alterations in the physical
and chemical properties of the ECM change during dis-
ease progression and how these changes ultimately influ-
ence resident cells and the potential of therapeutic
strategies to regenerate native tissue function. This study
is the first to use decellularization to study alterations in
the extracellular matrix of diseased tissue, and the results
described herein demonstrate how the altered matrix af-
fects the potential for therapeutic intervention.
Analysis of the decellularized infarct tissue revealed
significant alterations in both the mechanical and com-
positional properties of the ECM with remodeling time
after MI. Stiffness measurements of the decellularized
infarct followed trends similar to those derived from na-
tive, cellular scar tissue [33,47]. In general, infarct ECM
stiffness increased slightly immediately after infarction
Figure 9 MSC-conditioned media promotes cardiomyocyte
survival after oxidative stress. The conditioned-media samples
derived from MSCs cultured in the presence of matrix have a greater
ability to rescue oxidatively stressed cardiomyocytes as compared
with those cells cultured on TCP (P < 0.05) or media that has not
been conditioned by MSCs (P < 0.05). Conditioned media samples
from cells cultured on 4 week matrix have a greater ability to
prevent cardiomyocyte death as compared with cells cultured on
healthy matrix (P < 0.1) (n = 6).
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matic alterations in stiffness occurred during the later
stages of remodeling after CF activation, with a nearly
threefold increase in stiffness (2 and 4 weeks after MI).
However, it is important to note that the magnitude of
stiffness values varies greatly between native infarcted
tissue and decellularized infarcts. As previously reported,
decellularized tissues have mechanical properties that
are distinct from their native form [29], because the ab-
sence of cells increases the density of the ECM, thereby
increasing the overall apparent stiffness. In our cell-
culture platform, we chose to recapitulate the stiffness of
the cellularized infarct because it is more characteristic
of the microenvironment seen in vivo by implanted cells,
although investigations into the effects of higher stiffness
may be warranted in the future.
Assessment of collagen fibril content and alignment
via SHG of decellularized infarcts allows a unique meas-
ure of the dynamic changes in the organizational pat-
terns of collagen fibers as a function of time after MI.
Our imaging analysis confirmed earlier findings that elu-
cidated that the majority of all collagen fibers within the
scar are highly aligned [48]. Although the measured
SHG intensities within the image volume can be affected
by changes in the light-scattering properties of the tissue
and/or the microstructural organization of collagen
fibrils within the larger fiber bundles [49], a trend of
increasing SHG image intensity with post-MI time
points further supports evidence of increased collagen
deposition over time. Collectively, the compositional ana-
lysis and SHG imaging of decellularized tissue demonstrateincreased collagen deposition and organization into aligned
fiber bundles after infarct.
Alterations in scar mechanics are likely a result of the
changing composition and structural organization of the
matrix. Our findings are in accordance with previous
work [50] demonstrating an increase in total collagen
deposition after infarction, which serves to stabilize the
injured organ. Our work confirms the earlier finding that
the 4 week infarct contains more collagen than in either
the healthy or 1 week conditions [50]. LC-MS/MS ana-
lysis further confirmed this assessment, as the compos-
ition of the infarct at 4 weeks after MI consists nearly
entirely of collagen, whereas the healthy and 1 week
matrix is more diverse and composed of a variety of
matrix proteins.
It is important to note that this method of analysis has
a limited potential for identifying those proteins that are
present in relatively low abundance, because higher-
abundance proteins will comprise the majority of all
spectrum counts. In the 1 week infarct matrix, we ob-
served a decrease in collagen I, laminin, collagen IV, and
collagen XV. Phatharajaree et al. previously reported an
increase in MMP expression within 2 days and maximal
expression by 7 days after coronary artery ligation [51],
which could explain decreases in ECM protein content.
Although others have reported an increase in laminin
[52], collagen I [53], collagen III [53], and collagen IV
[54] gene expression immediately after MI, it is import-
ant to note the deposition of functional protein occurs
several days after the transcriptional activation of genes
[55]. Collagen XV is involved in matrix organization
within the heart, and its deficiency results in an in-
creased sensitivity to cardiac stress [56]. Its absence
within the LC-MS/MS spectrums derived from in-
farcted hearts supports our observation of disorganized
fibers via SHG imaging as early as 1 week post-MI.
We also show an increase in periostin, fibronectin, and
collagen XI within 1 week of artery ligation. Periostin
is critical for stabilizing the ventricle wall after infarc-
tion, and our findings support previous work, which
demonstrates that periostin expression is induced after
myocardial ischemia [57]. Other work has also demon-
strated a rapid increase in fibronectin [58] and collagen
VI expression [52] immediately after MI. Although fibro-
nectin has been identified for its beneficial role in wound
healing [59], collagen VI negatively affects cardiac func-
tion after MI (through increased cardiomyocyte apoptosis
and fibrosis, as compared with collagen VI-deficient
mice) [60].
The most dramatic alterations in protein content are
observed 4 weeks after coronary artery ligation with an
absence of several critical cardiac matrix proteins, in-
cluding periostin, elastin, collagen III, collagen V, and
collagen XV. These results suggest that the scar has
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lack of elastin [61] and collagen V [62]. The deposition
of newly synthesized matrix proteins is likely disorga-
nized, given the absence of collagen XV [56]. Overall,
the remodeled matrix is dominated by collagen content,
which increases the stiffness of the organ and minimizes
its capacity to function normally [63].
The striking difference between the remodeled and
native tissue is further illustrated by the capacity of
the different ECM to elicit early cardiac differentiation in
MSCs. The composition and stiffness of healthy myocar-
dium promoted early cardiac differentiation, as evidenced
by an increase in Nkx2.5 and GATA4 expression, as com-
pared with TCP. Although the early infarct matrix at
1 week did not negatively influence the expression of
either transcription factor, the increased stiffness charac-
teristic of the infarct significantly abrogated the differenti-
ation capacity of the cells. These results support previous
findings by Engler et al. [23], which demonstrated that
MSCs have a greater capacity for myogenic differentiation
on polyacrylamide gels of lower stiffness (10 kPa) as com-
pared with those of higher stiffness (100 kPa). In addition,
Tan et al. demonstrated that MSCs cultured on adsorbed
collagen V upregulated their expression of both Nkx2.5
and GATA4, as compared with collagen I [22]. This fol-
lows our finding, which demonstrated similar expression
levels of Nkx2.5 on gels with healthy and 1 week matrix,
which both contain similar abundances of collagen V. It is
important to note that the more significantly remodeled
matrix of the 4 week time point drastically altered the ex-
pression of both transcription factors. Although Nkx2.5
expression is negligible on either stiffness in the presence
of 4 week matrix, GATA4 expression is dramatically
enhanced by this matrix on the gel of increased stiffness
(40 kPa). This suggests that complex interactions occur
between stiffness and composition, which regulate MSC
differentiation. Further experiments are needed to identify
which individual peptides or proteins may be promoting
or inhibiting cardiac differentiation within the ECM of the
4 week infarct. By identifying additional matrix proteins
that influence cellular differentiation, we may be able to
manipulate the extracellular environment in vivo to en-
hance cellular differentiation and ultimately improve myo-
cardial regeneration.
Whereas literature provides conflicting evidence dem-
onstrating both an ability [37] and inability [36] of im-
planted MSCs to differentiate toward a cardiomyocyte
lineage, significant work has illustrated an ability of
MSCs to express cardiac specific markers including
Nkx2.5, GATA4, and α-actin within the infarct environ-
ment [35,64]. In particular, Quevedo et al. [34] observed
some capacity for cardiac differentiation when cells were
implanted in chronic cases of MI as compared with
acute intervention. These findings are in agreement withour system that identified that the composition and stiff-
ness of the later infarct environment was promoting
MSC expression of GATA4 as compared with the stiff-
ness and composition characteristic of the 1-week time
point. However, it is important to note that the MSCs
within our gel system did not express later cardiac tran-
scription factors, including Mef2c and Tbx5 (data not
shown), and were unable to differentiate into mature
cardiomyocytes.
Despite their limited potential for cardiac differenti-
ation, MSCs have still demonstrated an ability to restore
some minimal, although statistically significant, function
to the heart after MI during clinical trials, through the
presumed mechanism of paracrine signaling [11,12,65].
Therefore, we sought to investigate whether the release
of paracrine signals by MSCs is influenced by remodel-
ing time after MI. Previous work by Li et al. demon-
strated that the overexpression of GATA4 by MSCs
enhanced the therapeutic potential of these cells by in-
creasing their expression of particular growth factors
within the infarct environment [66]. In particular, proan-
giogenic growth factors are capable of improving left
ventricle function by increasing capillary density within
the scar and border zones of infarcted hearts when se-
creted by MSCs in vivo [13]. These factors include VEGF
[67], PGF [68], FGF2 [68], SDF1 [69], and HGF [70]. All
five of these factors demonstrated increased expression
by MSCs when cultured on the 4-week matrix (Figures 6
and 7), which suggests that the composition of the
chronically remodeled heart enhances the ability of these
cells to promote angiogenesis within the infarct.
In addition to their roles in angiogenesis, HGF and
SDF1 are recognized for their anti-fibrotic and cytoprotec-
tive roles within the injured myocardium. HGF signaling
is known to be integrin mediated [71] (the HGF receptor,
C-met, physically interacts with integrins and together
they regulate downstream processes [72]), but research
has also demonstrated that the overexpression of SDF1
leads to enhanced HGF signaling. Given that our results
reveal similar trends for both growth factors (increased
expression on 4 week matrix), it is unclear whether we are
observing an independent or combinatorial effect. Further
investigation is needed, but it is important to note that
AKT1 expression was also slightly elevated on the 4-week
matrix (Figure 6). AKT overexpression has been shown to
promote the release of paracrine signals by MSCs (thereby
increasing the benefit achieved after implantation) [36],
and its activation is integrin mediated [73]. Therefore, it is
possible that the expression of AKT1 is altered by matrix
composition and accounting, at least in part, for to the al-
terations in growth factor secretion observed. Functional
tests demonstrated that the upregulation of SDF1 and
HGF expression and secretion translated to improved sur-
vival for stressed cardiomyocytes in vitro.
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composition is influencing growth factor expression and
secretion is unclear, earlier work has demonstrated that
the differentiation potential of MSCs toward bone and
tendon lineages is driven by their paracrine profile,
which is modulated by matrix composition [74]. There-
fore, it follows that the release of paracrine signals
within the infarct environment is likely altered as a func-
tion of the remodeling time (which dramatically aug-
ments the composition of the matrix). The 4 week
matrix has the most striking alterations in composition
and therefore has the largest impact on paracrine signal-
ing by MSCs.
In addition, the bioavailability of growth factors within
the microenvironment may itself be influenced by the
matrix composition. Earlier work demonstrated that
VEGF has enhanced biologic activity on fibronectin and
vitronectin substrates, whereas PDGF has increased af-
finity for collagen substrates of various isoforms [75,76].
Therefore, it is possible that once the MSCs secrete
these soluble factors, they are maintained within the in-
farct matrix at varying affinities and bioavailabilities as a
function of matrix composition [77].
Last, the cellular response to growth-factor stimula-
tion is known to be integrin dependent. Cardiomyocyte
proliferation achieved via heparin-binding EGF-like
growth factor is dependent on β1-integrin stimulation.
This suggests a dynamic cross-talk between integrin ex-
pression and growth factor stimulation [27]. Although
further work is needed to identify which of these mech-
anisms is responsible for the measured effect of matrix
composition on soluble factor expression by MSCs, it is
clear that the therapeutic potential of these cells is en-
hanced within the extracellular environment of the re-
modeled infarct.
Although investigation into the therapeutic potential
of MSCs within the acutely infarcted heart is more com-
mon [78], several investigators have observed significant
repair by MSCs when injected 1 to 3 months after in-
farction [78-81]. For example, Miyahara et al. [80] dem-
onstrated that the implantation of MSCs 4 weeks after
coronary artery ligation promoted angiogenesis, reversed
wall thinning, and improved left ventricular function
[80]. These studies support our finding that MSCs main-
tain the potential to initiate significant repair against a
chronic infarct. It is also possible that the therapeutic
potential of these cells in the acute infarct will be en-
hanced after co-injection with matrix proteins that are
representative of the 4 week time point. Earlier work
demonstrated that the injection of decellularized porcine
ventricular ECM promoted angiogenesis via enhanced
arteriole formation [32], and we believe the co-injection
of matrix and MSCs will only further enhance this thera-
peutic strategy.Conclusions
This study demonstrates a novel mechanism by which
the extracellular environment of the infarct regulates the
therapeutic potential of MSCs. By specifically isolating
and characterizing the diseased matrix, we were able to
understand both its positive and negative influence on
cell therapy applications. Further work with this cell
culture system has the potential to increase both the
efficiency and efficacy of cell therapy treatment of MI, to
ultimately reduce the prevalence and severity of HF.
Additional file
Additional file 1: Figure S1. Collagen I-coated polyacrylamide gels
elicit minimal expression of cardiac transcription factors. Representative
histologic images of MSCs cultured on polyacrylamide gels coated with
Collagen I and stained for markers of Nkx2.5 and GATA4. Scale bar is
100 μm. Collagen I-coated gels (n = 1) and TCP (n = 5) elicit similar levels
of expression of Nkx2.5 and Gata4, as demonstrated through Western
blot analysis.
Abbreviations
AKT1: Protein kinase B; APS: ammonium persulfate; CF: cardiac fibroblast;
CVD: cardiovascular disease; ECL: enhanced chemiluminescence;
ECM: extracellular matrix; FGF2: fibroblast growth factor 2; HF: heart failure;
HGF: hepatocyte growth factor; IGF: insulin-like growth factor; IL-
10: interleukin 10; LC-MS/MS: liquid chromatography–tandem mass
spectroscopy; MI: myocardial infarction; MSC: mesenchymal stem cell;
NHS: N-hydroxysuccinimide; PA: polyacrylamide; PBS: phosphate-buffered
saline; PDGF: platelet-derived growth factor β; PGF: placental growth factor;
SDF1: stromal cell-derived factor 1; SDS: sodium dodecylsulfate; SHG: second
harmonic generation; TBST: Tris-buffered saline and 10% tween 20;
TCP: tissue culture plastic; TGF-βR2: transforming growth factor-β receptor II;
TNF-α: tumor necrosis factor-α; TPEF: two-photon excited fluorescence;
VEGF: vascular endothelial growth factor.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
KS carried out the in vivo animal work, characterized the alterations to
decellularized matrix composition and mechanics as a function of remodeling
time, developed the in vitro cell-culture platform and characterized cell fate
through protein and gene-expression assays. KQ acquired and analyzed the
SHG images. KT helped to develop the in vitro model system and collected
preliminary data. IG participated in the design and coordination of the SHG
image acquisition and analysis. LB conceived of the study, participated in its
design and coordination, and helped to draft the manuscript. All authors read
and approved the final manuscript.
Acknowledgements
This work was supported by the National Institutes of Health-National Heart,
Lung and Blood Institute (Award R00HL093358 to L.D.B.). We acknowledge
Mark Aronovitz for his assistance in the development of the in vivo model of
myocardial infarction.
Received: 30 May 2013 Revised: 8 November 2013
Accepted: 16 January 2014 Published: 24 January 2014
References
1. Rosamond W, Flegal K, Friday G, Furie K, Go A, Greenlund K, Haase N, Ho M,
Howard V, Kissela B, Kissela B, Kittner S, Lloyd-Jones D, McDermott M, Meigs J,
Moy C, Nichol G, O’Donnell CJ, Roger V, Rumsfeld J, Sorlie P, Steinberger J,
Thom T, Wasserthiel-Smoller S, Hong Y: Heart disease and stroke statistics,
2007 update: a report from the American Heart Association Statistics
Sullivan et al. Stem Cell Research & Therapy 2014, 5:14 Page 14 of 15
http://stemcellres.com/content/5/1/14Committee and Stroke Statistics Subcommittee. Circulation 2007,
115:e69–e171.
2. Nakamuta JS, Danoviz ME, Marques FLN, dos Santos L, Becker C, Gonçalves
GA, Vassallo PF, Schettert IT, Tucci PJF, Krieger JE: Cell therapy attenuates
cardiac dysfunction post myocardial infarction: effect of timing, routes of
injection and a fibrin scaffold. PLoS One 2009, 4:e6005.
3. Nelson TJ, Martinez-Fernandez A, Yamada S, Perez-Terzic C, Ikeda Y, Terzic A:
Repair of acute myocardial infarction by human stemness factors
induced pluripotent stem cells. Circulation 2009, 120:408–416.
4. Zhang M, Methot D, Poppa V, Fujio Y, Walsh K, Murry CE: Cardiomyocyte
grafting for cardiac repair: graft cell death and anti-death strategies.
J Mol Cell Cardiol 2001, 33:907–921.
5. Berry MF, Engler AJ, Woo YJ, Pirolli TJ, Bish LT, Jayasankar V, Morine KJ,
Gardner TJ, Discher DE, Sweeney HL: Mesenchymal stem cell injection
after myocardial infarction improves myocardial compliance. Am J Physiol
Heart Circ Physiol 2006, 290:H2196–H2203.
6. Wollert KC, Drexler H: Cell therapy for acute myocardial infarction: where
are we heading? Nat Clin Pract Cardiovasc Med 2004, 1:61.
7. Guo J, Lin G, Bao C, Hu Z, Hu M: Anti-inflammation role for mesenchymal stem
cells transplantation in myocardial infarction. Inflammation 2007, 30:97–104.
8. Das R, Jahr H, van Osch GJVM, Farrell E: The role of hypoxia in bone
marrow-derived mesenchymal stem cells: considerations for regenera-
tive medicine approaches. Tissue Eng Part B Rev 2010, 16:159–168.
9. Ly HQ, Hoshino K, Pomerantseva I, Kawase Y, Yoneyama R, Takewa Y, Fortier
A, Gibbs-Strauss SL, Vooght C, Frangioni JV, Hajjar RJ: In vivo myocardial
distribution of multipotent progenitor cells following intracoronary
delivery in a swine model of myocardial infarction. Eur Heart J 2009,
30:2861–2868.
10. Cleland JGF, Freemantle N, Coletta AP, Clark AL: Clinical trials update from
the American Heart Association: REPAIR-AMI, ASTAMI, JELIS, MEGA,
REVIVE-II, SURVIVE, and PROACTIVE. Eur J Heart Fail 2006, 8:105–110.
11. Hu X, Yu SP, Fraser JL, Lu Z, Ogle ME, Wang J-A, Wei L: Transplantation
of hypoxia-preconditioned mesenchymal stem cells improves infarcted
heart function via enhanced survival of implanted cells and angiogenesis.
J Thorac Cardiovasc Surg 2008, 135:799–808.
12. Mirotsou M, Zhang Z, Deb A, Zhang L, Gnecchi M, Noiseux N, Mu H, Pachori A,
Dzau V: Secreted frizzled related protein 2 (Sfrp2) is the key Akt-
mesenchymal stem cell-released paracrine factor mediating myocardial
survival and repair. Proc Natl Acad Sci U S A 2007, 104:1643–1648.
13. Tang YL, Zhao Q, Qin X, Shen L, Cheng L, Ge J, Phillips MI: Paracrine action
enhances the effects of autologous mesenchymal stem cell
transplantation on vascular regeneration in rat model of myocardial
infarction. Ann Thorac Surg 2005, 80:229–236. discussion 236–237.
14. Hocking AM, Gibran NS: Mesenchymal stem cells: paracrine signaling and
differentiation during cutaneous wound repair. Exp Cell Res 2010,
316:2213–2219.
15. Penn MS: Importance of the SDF-1:CXCR4 axis in myocardial repair.
Circ Res 2009, 104:1133–1135.
16. Gnecchi M, Zhang Z, Ni A, Dzau VJ: Paracrine mechanisms in adult stem
cell signaling and therapy. Circ Res 2008, 103:1204–1219.
17. Ranganath SH, Levy O, Inamdar MS, Karp JM: Harnessing the mesenchymal
stem cell secretome for the treatment of cardiovascular disease.
Cell Stem Cell 2012, 10:244–258.
18. Sullivan KE, Black LD: The role of cardiac fibroblasts in extracellular
matrix-mediated signaling during normal and pathological cardiac
development. J Biomech Eng 2013, 135:71001.
19. Bowers SLK, Banerjee I, Baudino TA: The extracellular matrix: at the center
of it all. J Mol Cell Cardiol 2010, 48:474–482.
20. Kim S-H, Turnbull J, Guimond S: Extracellular matrix and cell signalling: the
dynamic cooperation of integrin, proteoglycan and growth factor receptor.
J Endocrinol 2011, 209:139–151.
21. Adams JC, Watt FM: Regulation of development and differentiation by
the extracellular matrix. Development 1993, 117:1183–1198.
22. Tan G, Shim W, Gu Y, Qian L, Chung YY, Lim SY, Yong P, Sim E, Wong P:
Differential effect of myocardial matrix and integrins on cardiac
differentiation of human mesenchymal stem cells. Differentiation 2010,
79:260–271.
23. Engler AJ, Sen S, Sweeney HL, Discher DE: Matrix elasticity directs stem
cell lineage specification. Cell 2006, 126:677–689.
24. Reilly GC, Engler AJ: Intrinsic extracellular matrix properties regulate stem
cell differentiation. J Biomech 2010, 43:55–62.25. Rowlands AS, George PA, Cooper-White JJ: Directing osteogenic and
myogenic differentiation of MSCs: interplay of stiffness and adhesive
ligand presentation. Am J Physiol Cell Physiol 2008, 295:C1037–C1044.
26. Byfield FJ, Wen Q, Levental I, Nordstrom K, Arratia PE, Miller RT, Janmey PA:
Absence of filamin A prevents cells from responding to stiffness
gradients on gels coated with collagen but not fibronectin. Biophys J
2009, 96:5095–5102.
27. Ieda M, Tsuchihashi T, Ivey KN, Ross RS, Hong T-T, Shaw RM, Srivastava D:
Cardiac fibroblasts regulate myocardial proliferation through beta1
integrin signaling. Dev Cell 2009, 16:233–244.
28. Gershlak JR, Resnikoff JIN, Sullivan KE, Williams C, Wang RM, Black LD:
Mesenchymal stem cells ability to generate traction stress in response to
substrate stiffness is modulated by the changing extracellular matrix
composition of the heart during development. Biochem Biophys Res
Commun 2013, 439:161–166.
29. Ott HC, Matthiesen TS, Goh S-K, Black LD, Kren SM, Netoff TI, Taylor DA:
Perfusion-decellularized matrix: using nature’s platform to engineer a
bioartificial heart. Nat Med 2008, 14:213–221.
30. Williams C, Quinn KP, Georgakoudi I, Black LD: Young developmental age
cardiac extracellular matrix promotes the expansion of neonatal
cardiomyocytes in vitro. Acta Biomater 2014, 10:194–204.
31. French KM, Boopathy AV, DeQuach JA, Chingozha L, Lu H, Christman KL,
Davis ME: A naturally derived cardiac extracellular matrix enhances
cardiac progenitor cell behavior in vitro. Acta Biomater 2012, 8:4357–4364.
32. Singelyn JM, DeQuach JA, Seif-Naraghi SB, Littlefield RB, Schup-Magoffin PJ,
Christman KL: Naturally derived myocardial matrix as an injectable
scaffold for cardiac tissue engineering. Biomaterials 2009, 30:5409–5416.
33. Fomovsky GM, Holmes JW: Evolution of scar structure, mechanics, and
ventricular function after myocardial infarction in the rat. Am J Physiol
Heart Circ Physiol 2010, 298:H221–H228.
34. Quevedo HC, Hatzistergos KE, Oskouei BN, Feigenbaum GS, Rodriguez JE,
Valdes D, Pattany PM, Zambrano JP, Hu Q, McNiece I, Heldman AW, Hare
JM: Allogeneic mesenchymal stem cells restore cardiac function in
chronic ischemic cardiomyopathy via trilineage differentiating capacity.
Proc Natl Acad Sci U S A 2009, 106:14022–14027.
35. Rose RA, Jiang H, Wang X, Helke S, Tsoporis JN, Gong N, Keating SCJ,
Parker TG, Backx PH, Keating A: Bone marrow-derived mesenchymal
stromal cells express cardiac-specific markers, retain the stromal
phenotype, and do not become functional cardiomyocytes in vitro.
Stem Cells 2008, 26:2884–2892.
36. Noiseux N, Gnecchi M, Lopez-Ilasaca M, Zhang L, Solomon SD, Deb A,
Dzau VJ, Pratt RE: Mesenchymal stem cells overexpressing Akt
dramatically repair infarcted myocardium and improve cardiac
function despite infrequent cellular fusion or differentiation. Mol Ther
2006, 14:840–850.
37. Mangi AA, Noiseux N, Kong D, He H, Rezvani M, Ingwall JS, Dzau VJ:
Mesenchymal stem cells modified with Akt prevent remodeling and
restore performance of infarcted hearts. Nat Med 2003, 9:1195–1201.
38. Quinn KP, Bellas E, Fourligas N, Lee K, Kaplan DL, Georgakoudi I:
Characterization of metabolic changes associated with the functional
development of 3D engineered tissues by non-invasive, dynamic
measurement of individual cell redox ratios. Biomaterials 2012,
33:5341–5348.
39. Black LD, Brewer KK, Morris SM, Schreiber BM, Toselli P, Nugent MA, Suki B,
Stone PJ: Effects of elastase on the mechanical and failure properties of
engineered elastin-rich matrices. J Appl Physiol 2005, 98:1434–1441.
40. Spotnitz HM: Macro design, structure, and mechanics of the left ventricle.
J Thorac Cardiovasc Surg 2000, 119:1053–1077.
41. DeQuach JA, Mezzano V, Miglani A, Lange S, Keller GM, Sheikh F,
Christman KL: Simple and high yielding method for preparing tissue
specific extracellular matrix coatings for cell culture. PLoS One 2010,
5:e13039.
42. Freytes DO, Martin J, Velankar SS, Lee AS, Badylak SF: Preparation and
rheological characterization of a gel form of the porcine urinary
bladder matrix. Biomaterials 2008, 29:1630–1637.
43. Wang YL, Pelham RJ: Preparation of a flexible, porous polyacrylamide
substrate for mechanical studies of cultured cells. Methods Enzymol 1998,
298:489–496.
44. Syedain ZH, Weinberg JS, Tranquillo RT: Cyclic distension of fibrin-based
tissue constructs: evidence of adaptation during growth of engineered
connective tissue. Proc Natl Acad Sci U S A 2008, 105:6537–6542.
Sullivan et al. Stem Cell Research & Therapy 2014, 5:14 Page 15 of 15
http://stemcellres.com/content/5/1/1445. Nakamura T, Mizuno S, Matsumoto K, Sawa Y, Matsuda H: Myocardial
protection from ischemia/reperfusion injury by endogenous and
exogenous HGF. J Clin Invest 2000, 106:1511–1519.
46. Zhang X, Azhar G, Nagano K, Wei JY: Differential vulnerability to oxidative
stress in rat cardiac myocytes versus fibroblasts. J Am Coll Cardiol 2001,
38:2055–2062.
47. Connelly CM, Vogel WM, Wiegner AW, Osmers EL, Bing OH, Kloner RA,
Dunn-Lanchantin DM, Franzblau C, Apstein CS: Effects of reperfusion after
coronary artery occlusion on post-infarction scar tissue. Circ Res 1985,
57:562–577.
48. Holmes JW, Borg TK, Covell JW: Structure and mechanics of healing
myocardial infarcts. Annu Rev Biomed Eng 2005, 7:223–253.
49. Lacomb R, Nadiarnykh O, Townsend SS, Campagnola PJ: Phase matching
considerations in second harmonic generation from tissues: effects on
emission directionality, conversion efficiency and observed morphology.
Opt Commun 2008, 281:1823–1832.
50. Jugdutt BI, Joljart MJ, Khan MI: Rate of collagen deposition during healing
and ventricular remodeling after myocardial infarction in rat and dog
models. Circulation 1996, 94:94–101.
51. Phatharajaree W, Phrommintikul A, Chattipakorn N: Matrix metalloproteinases
and myocardial infarction. Can J Cardiol 2007, 23:727–733.
52. Dinh W, Bansemir L, Füth R, Nickl W, Stasch J-P, Coll-Barroso M, Lapp H,
Bufe A, Wolfertz J, Scheffold T, Lankisch M: Increased levels of laminin and
collagen type VI may reflect early remodelling in patients with acute
myocardial infarction. Acta Cardiol 2009, 64:329–334.
53. Cleutjens JP, Verluyten MJ, Smiths JF, Daemen MJ: Collagen remodeling after
myocardial infarction in the rat heart. Am J Pathol 1995, 147:325–338.
54. Morishita N, Kusachi S, Yamasaki S, Kondo J, Tsuji T: Sequential changes in
laminin and type IV collagen in the infarct zone: immunohistochemical
study in rat myocardial infarction. Jpn Circ J 1996, 60:108–114.
55. Le Roch KG, Johnson JR, Florens L, Zhou Y, Santrosyan A, Grainger M,
Yan SF, Williamson KC, Holder AA, Carucci DJ, Yates JR, Winzeler EA:
Global analysis of transcript and protein levels across the Plasmodium
falciparum life cycle. Genome Res 2004, 14:2308–2318.
56. Rasi K, Piuhola J, Czabanka M, Sormunen R, Ilves M, Leskinen H, Rysä J,
Kerkelä R, Janmey P, Heljasvaara R, Peuhkurinen K, Vuolteenaho O, Ruskoaho
H, Vajkoczy P, Pihlajaniemi T, Eklund L: Collagen XV is necessary for
modeling of the extracellular matrix and its deficiency predisposes to
cardiomyopathy. Circ Res 2010, 107:1241–1252.
57. Shimazaki M, Nakamura K, Kii I, Kashima T, Amizuka N, Li M, Saito M, Fukuda
K, Nishiyama T, Kitajima S, Saga Y, Fukayama M, Sata M, Kudo A: Periostin is
essential for cardiac healing after acute myocardial infarction. J Exp Med
2008, 205:295–303.
58. Van Dijk A, Niessen HWM, Ursem W, Twisk JWR, Visser FC, van Milligen FJ:
Accumulation of fibronectin in the heart after myocardial infarction: a
putative stimulator of adhesion and proliferation of adipose-derived
stem cells. Cell Tissue Res 2008, 332:289–298.
59. Ulrich MM, Janssen AM, Daemen MJ, Rappaport L, Samuel JL, Contard F,
Smits JF, Cleutjens JP: Increased expression of fibronectin isoforms after
myocardial infarction in rats. J Mol Cell Cardiol 1997, 29:2533–2543.
60. Luther DJ, Thodeti CK, Shamhart PE, Adapala RK, Hodnichak C, Weihrauch D,
Bonaldo P, Chilian WM, Meszaros JG: Absence of type VI collagen paradoxically
improves cardiac function, structure, and remodeling after myocardial
infarction. Circ Res 2012, 110:851–856.
61. Li S-H, Sun Z, Guo L, Han M, Wood MFG, Ghosh N, Vitkin IA, Weisel RD,
Li R-K: Elastin overexpression by cell-based gene therapy preserves
matrix and prevents cardiac dilation. J Cell Mol Med 2012, 16:2429–2439.
62. Chen CZ, Raghunath M: Focus on collagen: in vitro systems to study
fibrogenesis and antifibrosis state of the art. Fibrogenesis Tissue Repair
2009, 2:7.
63. Brilla CG, Rupp H: Myocardial collagen matrix remodeling and congestive
heart failure. Cardiologia 1994, 39:389–393.
64. Kawada H, Fujita J, Kinjo K, Matsuzaki Y, Tsuma M, Miyatake H, Muguruma Y,
Tsuboi K, Itabashi Y, Ikeda Y, Ogawa S, Okano H, Hotta T, Ando K, Fukuda K:
Nonhematopoietic mesenchymal stem cells can be mobilized and
differentiate into cardiomyocytes after myocardial infarction. Blood 2004,
104:3581–3587.
65. Mazhari R, Hare JM: Mechanisms of action of mesenchymal stem cells in
cardiac repair: potential influences on the cardiac stem cell niche.
Nat Clin Pract Cardiovasc Med 2007, 4:S21–S26.66. Li H, Zuo S, He Z, Yang Y, Pasha Z, Wang Y, Xu M: Paracrine factors
released by GATA-4 overexpressed mesenchymal stem cells increase
angiogenesis and cell survival. Am J Physiol Heart Circ Physiol 2010,
299:H1772–H1781.
67. Sadat S, Gehmert S, Song Y-H, Yen Y, Bai X, Gaiser S, Klein H, Alt E:
The cardioprotective effect of mesenchymal stem cells is mediated by
IGF-I and VEGF. Biochem Biophys Res Commun 2007, 363:674–679.
68. Uemura R, Xu M, Ahmad N, Ashraf M: Bone marrow stem cells prevent left
ventricular remodeling of ischemic heart through paracrine signaling.
Circ Res 2006, 98:1414–1421.
69. Tang J, Wang J, Yang J, Kong X, Zheng F, Guo L, Zhang L, Huang Y:
Mesenchymal stem cells over-expressing SDF-1 promote angiogenesis
and improve heart function in experimental myocardial infarction in rats.
Eur J Cardiothorac Surg 2009, 36:644–650.
70. Deuse T, Peter C, Fedak PWM, Doyle T, Reichenspurner H, Zimmermann
WH, Eschenhagen T, Stein W, Wu JC, Robbins RC, Schrepfer S: Hepatocyte
growth factor or vascular endothelial growth factor gene transfer
maximizes mesenchymal stem cell-based myocardial salvage after acute
myocardial infarction. Circulation 2009, 120:S247–S254.
71. Chan P-C, Chen S-Y, Chen C-H, Chen H-C: Crosstalk between hepatocyte
growth factor and integrin signaling pathways. J Biomed Sci 2006,
13:215–223.
72. Zhang Y-W, Vande Woude GF: HGF/SF-met signaling in the control of
branching morphogenesis and invasion. J Cell Biochem 2003, 88:408–417.
73. Pankov R, Cukierman E, Clark K, Matsumoto K, Hahn C, Poulin B, Yamada
KM: Specific beta1 integrin site selectively regulates Akt/protein kinase B
signaling via local activation of protein phosphatase 2A. J Biol Chem
2003, 278:18671–18681.
74. Sharma RI, Snedeker JG: Paracrine interactions between mesenchymal
stem cells affect substrate driven differentiation toward tendon and
bone phenotypes. PLoS One 2012, 7:e31504.
75. Lin H, Chen B, Sun W, Zhao W, Zhao Y, Dai J: The effect of collagen-
targeting platelet-derived growth factor on cellularization and
vascularization of collagen scaffolds. Biomaterials 2006, 27:5708–5714.
76. Lomas AC, Mellody KT, Freeman LJ, Bax DV, Shuttleworth CA, Kielty CM:
Fibulin-5 binds human smooth-muscle cells through alpha5beta1 and
alpha4beta1 integrins, but does not support receptor activation.
Biochem J 2007, 405:417–428.
77. Ball SG, Shuttleworth CA, Kielty CM: Mesenchymal stem cells and
neovascularization: role of platelet-derived growth factor receptors.
J Cell Mol Med 2007, 11:1012–1030.
78. Silva GV, Litovsky S, Assad JAR, Sousa ALS, Martin BJ, Vela D, Coulter SC, Lin
J, Ober J, Vaughn WK, Branco RVC, Oliveira EM, He R, Geng Y-J, Willerson JT,
Perin EC: Mesenchymal stem cells differentiate into an endothelial
phenotype, enhance vascular density, and improve heart function in a
canine chronic ischemia model. Circulation 2005, 111:150–156.
79. Behfar A, Yamada S, Crespo-Diaz R, Nesbitt JJ, Rowe LA, Perez-Terzic C,
Gaussin V, Homsy C, Bartunek J, Terzic A: Guided cardiopoiesis enhances
therapeutic benefit of bone marrow human mesenchymal stem cells in
chronic myocardial infarction. J Am Coll Cardiol 2010, 56:721–734.
80. Miyahara Y, Nagaya N, Kataoka M, Yanagawa B, Tanaka K, Hao H, Ishino K,
Ishida H, Shimizu T, Kangawa K, Sano S, Okano T, Kitamura S, Mori H:
Monolayered mesenchymal stem cells repair scarred myocardium after
myocardial infarction. Nat Med 2006, 12:459–465.
81. Schuleri KH, Feigenbaum GS, Centola M, Weiss ES, Zimmet JM, Turney J,
Kellner J, Zviman MM, Hatzistergos KE, Detrick B, Conte JV, McNiece I,
Steenbergen C, Lardo AC, Hare JM: Autologous mesenchymal stem cells
produce reverse remodelling in chronic ischaemic cardiomyopathy.
Eur Heart J 2009, 30:2722–2732.
doi:10.1186/scrt403
Cite this article as: Sullivan et al.: Extracellular matrix remodeling
following myocardial infarction influences the therapeutic potential of
mesenchymal stem cells. Stem Cell Research & Therapy 2014 5:14.
